Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer

ZHANG Guangquan; LU Qi; YAN Dan; XU Silu

doi:10.6039/j.issn.1001-0408.2024.12.20

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer

更新时间：2024-06-25

- Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 12, Pages: 1527-1532(2024)
- 作者机构：
  
  1.常州市肿瘤医院药事科，江苏常州　213032
  2.江苏省肿瘤医院/ 江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院药学部，南京　210009
  3.徐州市肿瘤医院药剂科，江苏徐州　221005
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.20
  CLC： R969.3
- Published：30 June 2024，
  
  Received：18 December 2023，
  
  Revised：11 May 2024，
扫描看全文
张广全,鹿琦,燕丹等.1例晚期乳腺癌并发甲状腺癌患者重启蒽环类药物化疗的药学监护 ^Δ[J].中国药房,2024,35(12):1527-1532.

ZHANG Guangquan,LU Qi,YAN Dan,et al.Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer[J].ZHONGGUO YAOFANG,2024,35(12):1527-1532.
张广全,鹿琦,燕丹等.1例晚期乳腺癌并发甲状腺癌患者重启蒽环类药物化疗的药学监护 ^Δ[J].中国药房,2024,35(12):1527-1532. DOI： 10.6039/j.issn.1001-0408.2024.12.20.

ZHANG Guangquan,LU Qi,YAN Dan,et al.Pharmaceutical care of reactivating anthracycline chemotherapy in a patient with advanced breast cancer combined with thyroid cancer[J].ZHONGGUO YAOFANG,2024,35(12):1527-1532. DOI： 10.6039/j.issn.1001-0408.2024.12.20.

摘要

目的

探讨晚期乳腺癌并发甲状腺癌患者重启蒽环类药物的药学监护思路。

方法

临床药师全程参与1例晚期乳腺癌合并甲状腺癌患者的治疗过程，为患者提供个体化用药建议。考虑患者存在多种抗肿瘤药物原发耐药，临床药师建议重新启用EC解救方案（静脉滴注表柔比星140 mg和环磷酰胺1 g，d

，21 d为一周期），并结合患者体重变化估算表柔比星终生累积剂量及最佳化疗疗程；针对患者化疗期间促甲状腺激素（TSH）水平异常波动可能增加心脏毒性发生风险的问题，临床药师建议根据TSH目标范围和检测结果，采取“前快后慢”的左甲状腺激素钠片剂量调整策略。

结果

医师采纳药师建议；临床药师协助医师重启以蒽环类药物为基础的7周期联合治疗方案。期间患者未出现明显心脏不良事件，病情稳定；左甲状腺素钠片加量后患者TSH水平稳步下降，未出现相关不良反应。

结论

对多种抗肿瘤药物原发耐药的乳腺癌并发甲状腺癌患者，在必要时可重新启用蒽环类药物，但启用前应进行基线心功能检查及甲状腺激素水平检测，并结合患者既往病史开展心脏毒性风险评估。临床药师应积极发挥专业优势，对此类患者开展全程药学监护，保障患者用药安全。

Abstract

OBJECTIVE

To explore the pharmaceutical care of reactivating anthracycline chemotherapy in patients with advanced breast cancer complicated with thyroid cancer.

METHODS

Clinical pharmacists participated in the whole treatment process of a patient with advanced breast cancer complicated with thyroid cancer and provided personalized medication recommendations. Considering that the patient currently has multiple primary anti-tumor drug resistance， clinical pharmacists recommend reactivating the EC rescue protocol （intravenous infusion of epirubicin hydrochloride 140 mg+cyclophosphamide 1 g， d

， 21 days for a cycle）. The cumulative lifetime dose of epirubicin and the optimal course of chemotherapy was estimated according to the body weight change of the patient. Given the issue that abnormal fluctuation of thyroid stimulating hormone （TSH） level during chemotherapy may increase the risk of cardiac toxicity， clinical pharmacists suggest adopting a dose adjustment strategy of “fast first and slow later” for Levothyroxine sodium tablet according to the target range of TSH and test results.

RESULTS

The doctors adopted the pharmacists’ suggestion； the clinical pharmacists assisted the doctors in reactivating the anthracycline-based 7-cycle combination regimen， during which the patient had no significant cardiac adverse events and was repeatedly evaluated as stable. TSH decreased steadily after Levothyroxine sodium tablets were added， and no adverse reaction related to TSH inhibition was observed.

CONCLUSIONS

Patients with primary drug-resistant breast cancer complicated with thyroid cancer may be reactived anthracyclines if necessary， but baseline cardiac function and thyroid hormone levels should be tested before initiation， and cardiac toxicity risk assessment should be performed in combination with the patient’s history. Clinical pharmacists should actively exert their professional advantages to carry out whole-process pharmaceutical care for such patients， so as to ensure the safety of drug use for patients.

关键词

蒽环类药物乳腺癌甲状腺癌药学监护临床药师

Keywords

breast cancerthyroid cancerpharmaceutical careclinical pharmacist

references

LIN N U，VANDERPLAS A，HUGHES M E，et al. Clinicopathologic features，patterns of recurrence，and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network[J]. Cancer，2012，118（22）：5463-5472.

IKEDA Y，KIYOTANI K，YEW P Y，et al. Germline PARP4 mutations in patients with primary thyroid and breast cancers[J]. Endocr Relat Cancer，2016，23（3）：171-179.

DELITALA A P，FANCIULLI G，MAIOLI M，et al. Subclinical hypothyroidism，lipid metabolism and cardiovascular disease[J]. Eur J Intern Med，2017，38：17-24.

中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）乳腺癌诊断和治疗指南2022[M].北京：人民健康出版社，2022：95-103.

Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology（CSCO）guidelines for the diagnosis and treatment of breast cancer 2022[M]. Beijing：People’s Health Publi-shing House，2022：95-103.

张剑. 中国蒽环类药物治疗乳腺癌专家共识[J]. 癌症，2021，40（11）：475-485.

ZHANG J. Expert consensus of anthracycline drugs in the treatment of breast cancer in China[J]. Chin J Cancer，2021，40（11）：475-485.

LOTRIONTE M，BIONDI-ZOCCAI G，ABBATE A，et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity[J]. Am J Cardiol，2013，112（12）：1980-1984.

RENEHAN A G，HARVIE M，CUTRESS R I，et al. How to manage the obese patient with cancer[J]. J Clin Oncol，2016，34（35）：4284-4294.

MICHEL L，MINCU R I，MAHABADI A A，et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients：a meta-analysis[J]. Eur J Heart Fail，2020，22（2）：350-361.

ROBERT J，MORVAN V L，SMITH D，et al. Predicting drug response and toxicity based on gene polymorphisms[J]. Crit Rev Oncol Hematol，2005，54（3）：171-196.

MACEDO A V S，HAJJAR L A，LYON A R，et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer[J]. JACC Cardio Oncol，2019，1（1）：68-79.

CORREMANS R，ADÃO R，DE KEULENAER G W，et al. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity[J]. Clin Exp Pharmacol Physiol，2019，46（3）：204-215.

LIPSHULTZ S E，GIANTRIS A L，LIPSITZ S R，et al. Doxorubicin administration by continuous infusion is not cardioprotective：the Dana-Farber 91-01 acute lymphoblastic leukemia protocol[J]. J Clin Oncol，2002，20（6）：1677-1682.

胡志强，余文韬，姚文秀，等. 抗肿瘤药物致心脏毒性及其防治措施的研究进展[J]. 中国药房，2020，31（2）：250-256.

HU Z Q，YU W T，YAO W X，et al. Research progress on cardiotoxicity caused by antineoplastic drugs and its prevention and treatment measures[J]. China Pharm，2020，31（2）：250-256.

O’BRIEN M E R，WIGLER N，INBAR M，et al. Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl（CAELYX/Doxil）versus conventional doxorubicin for first-line treatment of metastatic breast cancer[J]. Ann Oncol，2004，15（3）：440-449.

CHEN S，WU F，HAI R，et al. Thyroid disease is asso-ciated with an increased risk of breast cancer：a systematic review and meta-analysis[J]. Gland Surg，2021，10（1）：336-346.

岑福俊，杨剑波. 乳腺癌患者甲状腺激素和自身抗体的水平及临床意义[J]. 癌症进展，2019，17（18）：2180-2182，2191.

CEN F J，YANG J B. The levels and clinical significance of thyroid hormone and autoantibody in breast cancer patients[J]. Oncol Prog，2019，17（18）：2180-2182，2191.

KLEIN HESSELINK E N，KLEIN HESSELINK M S，DE BOCK G H，et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma：an observational study[J]. J Clin Oncol，2013，31（32）：4046-4053.

LIM H J，AHN S H，HONG S，et al. The relationship between subclinical thyroid disease and cardiovascular di-sease risk score in Koreans[J]. J Korean Med Sci，2017，32（10）：1626-1632.

HAUGEN B R，ALEXANDER E K，BIBLE K C，et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differen-tiated thyroid cancer：the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid，2016，26（1）：1-133.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmaceutical care for a case of infective endocarditis caused by Micrococcus luteus complicated with severe pneumonia

Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis

Rational use management standards of national key monitoring drug

Application practice of drug clinical comprehensive evaluation thinking in management of temporary drug purchase in hospital

Related Author

WANG Siyun

CHEN Junjun

ZHU Yuhui

LI Xin

ZHANG Xinru

WU Xia

ZHAO Yinlong

ZHANG Zhiqing

Related Institution

Dept. of Pharmacy， the Second Hospital of Jilin University

Dept. of Pharmacy， the Second Hospital of Hebei Medical University

ICU， Department of Anesthesiology， the Second Hospital of Hebei Medical University

Dept. of Pharmacy， Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital

Personalized Drug Therapy Key Laboratory of Sichuan Province， School of Medicine， University of Electronic Science and Technology of China

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰